German government to abandon variable drug discounting plans, source tells Reuters - Finance news and analysis from Global Banking & Finance Review
Finance

German government to abandon variable drug discounting plans, source tells Reuters

Published by Global Banking & Finance Review

Posted on June 15, 2026

2 min read

· Last updated: June 15, 2026

Add as preferred source on Google

Germany Replaces Variable Drug Discounts with Fixed Rates in Healthcare Overhaul

Government Policy Changes and Industry Response

By Andreas Rinke

Background on the Proposed Variable Discounts

BERLIN, June 15 (Reuters) - Germany's government is replacing plans that would have introduced variable discounts on pharmaceuticals, a government source told Reuters on Monday, following opposition from the industry to the proposal.

As part of the initial government plans, drug companies would have been obliged to offer price discounts that would vary depending on the country's overall expenditures for drugs and on revenues of the healthcare system.

Shift to Fixed-Level Discounts

The variable discounts will be replaced with new discounts at a fixed level so that companies can plan ahead, the source said, without specifying the size of the new discounts.

The federal health ministry said nothing had been decided yet and declined to comment further on any "parliamentary deliberations".

Healthcare System Overhaul and Financial Implications

  The government in April unveiled plans for a wide-ranging overhaul of the country's statutory healthcare system to reduce a looming funding gap by 20 billion euros ($23 billion) and to head off a hike in mandatory health insurance premiums.

Industry and Stakeholder Reactions

That prompted criticism by groups representing physicians, patients and hospitals, as well as drug industry leaders, some of whom said they would slash existing or future investment plans in response.

Impact on Pharmaceutical Investments

The CEO of Eli Lilly CEO had said the U.S. maker of obesity drugs would halve its originally planned investment of €2.3 billion ($2.7 billion) in Germany.

Views from Pharmaceutical Associations

When asked for comment, the German association of innovative pharmaceutical companies, VFA, said it had previously "highlighted the importance of a thorough impact assessment" of the planned price cuts.  

Further considerations were now up to the "democratic decision-making process", it added.

Additional Information

($1 = 0.8618 euros)

(Writing by Ludwig Burger;Editing by Thomas Seythal, Matthias Williams, Peter Graff)

Key Takeaways

  • Variable pharmaceutical discount plan dropped; replaced by fixed-level discounts for planning certainty
  • Healthcare reform aims to close a €20 billion funding gap to avoid mandatory insurance premium hikes
  • Major drugmakers like Eli Lilly and Boehringer Ingelheim are reducing investments in Germany amid reform-induced uncertainty

Frequently Asked Questions

Why is Germany abandoning variable drug discounting plans?
Germany is replacing variable drug discounting due to industry opposition and concerns over future investments.
What will replace the variable drug discount system in Germany?
The German government plans to introduce fixed-level discounts on pharmaceuticals to give companies more planning certainty.
How does the new drug discount policy affect the healthcare reform?
The shift aims to help address a funding gap in Germany's healthcare system and avoid hikes in health insurance premiums.
What was the pharmaceutical industry’s reaction to the original discount proposals?
Industry leaders warned of reduced or cancelled investments in Germany due to the impact of variable discounts.
Has the final size of the fixed drug discounts been specified?
No, the exact size of the new fixed discounts has not yet been specified by government sources.

Tags

Related Articles

More from Finance

Explore more articles in the Finance category